文献速递老年综合评估衰弱、肌少症与跌倒老年慢病共病管理

西妥昔单抗对比甲氨蝶呤一线治疗老年衰弱复发或转移性头颈癌:ELAN UNFIT随机III期试验

Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Healthy Longev · 2024-01-01

该随机开放III期试验纳入82例70岁及以上、经ELAN老年评估判定为衰弱、ECOG 0-2的复发或转移性头颈鳞癌患者,比较西妥昔单抗与甲氨蝶呤的疗效与安全性。

要点

  • 西妥昔单抗未改善衰弱老年头颈癌患者的无失败生存期,研究因无效提前终止。
  • ECOG评分2分的患者未从这些全身治疗中获益。
  • 建议在ELAN老年评估后探索免疫治疗等新选择。

核心结论

  • 西妥昔单抗对比甲氨蝶呤未改善老年衰弱复发或转移性头颈鳞癌患者的无失败生存期。

研究设计与样本

  • 在法国20家医院开展的随机、开放标签、III期试验,纳入82例70岁及以上、经ELAN老年评估判定为衰弱、ECOG 0-2的复发或转移性头颈鳞癌一线治疗患者。
  • 患者1:1随机分配接受西妥昔单抗500 mg/m2每2周静脉给药或甲氨蝶呤40 mg/m2每周静脉给药。

主要发现

  • 西妥昔单抗组63%(26/41)和甲氨蝶呤组73%(30/41)的患者发生3级或以上不良事件。
  • 西妥昔单抗组常见3-4级不良事件为乏力(4/41,10%)、肺部感染(4/41,10%)和痤疮样皮疹(4/41,10%);甲氨蝶呤组为乏力(9/41,22%)、γ-谷氨酰转移酶升高(7/41,17%)、钠血症(4/41,10%)、贫血(4/41,10%)、白细胞减少(4/41,10%)和中性粒细胞减少(4/41,10%)。
  • 西妥昔单抗组44%(18/41)和甲氨蝶呤组39%(16/41)的患者发生严重不良事件;西妥昔单抗组4例、甲氨蝶呤组2例发生致死性不良事件。

关键数值与推荐

  • 入组标准:年龄70岁及以上,经ELAN老年评估判定为衰弱,ECOG体能状态0-2,复发或转移性头颈鳞癌一线治疗。
  • 主要终点无失败生存期定义为从随机化至疾病进展、死亡、治疗中断或日常生活活动能力量表评分下降2分及以上(以先发生者为准)。

临床怎么用

  • 对于经ELAN老年评估判定为衰弱的老年复发或转移性头颈鳞癌患者,西妥昔单抗或甲氨蝶呤单药全身治疗均未显示显著获益。
  • ECOG体能状态2分的患者未从这些全身治疗中获益,应谨慎选择。
  • 建议在初始老年评估后探索包括免疫治疗在内的新治疗选择。

局限性

  • 研究因无效性期中分析提前终止,实际入组82例,低于计划样本量164例。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: At present, there is no established standard treatment for frail older patients with recurrent or metastatic head and neck squamous cell carcinoma. We aimed to compare the efficacy and safety of cetuximab to those of methotrexate (the reference regimen) in this population. METHODS: This randomised, open-label, phase 3 trial was done at 20 hospitals in France. Patients aged 70 years or older, assessed as frail by the ELAN Geriatric Evaluation, with recurrent or metastatic head and neck squamous cell carcinoma in the first-line setting and with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 were eligible for inclusion. Patients were randomly assigned (1:1) to receive cetuximab 500 mg/m2 intravenously every 2 weeks or methotrexate 40 mg/m2 intravenously every week, with minimisation by ECOG performance status, type of disease evolution, Charlson Comorbidity Index score, serum albumin concentration, and geriatrician consultation. To avoid deterministic minimisation and assure allocation concealment, patients were allocated with a probability of 0·80 to the treatment that most reduced the imbalance. Treatment was continued until disease progression or unacceptable toxicity, whichever occurred first. The primary endpoint was failure-free survival (defined as the time from randomisation to disease progression, death, discontinuation of treatment, or loss of 2 or more points on the Activities in Daily Living scale, whichever occurred first) and was analysed in the intention-to-treat population. 151 failures expected out of 164 patients were required to detect a hazard ratio (HR) of 0·625 with 0·05 alpha error, with 80% power. A futility interim analysis was planned when approximately 80 failures were observed, based on failure-free survival. Safety analyses included all patients who received at least one dose of the study drug. This study is registered on ClinicalTrials.gov (NCT01884623) and was stopped for futility after the interim analysis. FINDINGS: Between Nov 7, 2013, and April 23, 2018, 82 patients were enrolled (41 to the cetuximab group and 41 to the methotrexate group); 60 (73%) were male, 37 (45%) were aged 80 years or older, 35 (43%) had an ECOG performance status of 2, and 36 (44%) had metastatic disease. Enrolment was stopped for futility at the interim analysis. At the final analysis, median follow-up was 43·3 months (IQR 30·8-52·1). At data cutoff, all 82 patients had failure; failure-free survival did not differ significantly between the groups (median 1·4 months [95% CI 1·0-2·1] in the cetuximab group vs 1·9 months [1·1-2·6] in the methotrexate group; adjusted HR 1·03 [95% CI 0·66-1·61], p=0·89). The frequency of patients who had grade 3 or worse adverse events was 63% (26 of 41) in the cetuximab group and 73% (30 of 41) in the methotrexate group. The most common grade 3-4 adverse events in the cetuximab group were fatigue (four [10%] of 41 patients), lung infection (four [10%]), and rash acneiform (four [10%]), and those in the methotrexate group were fatigue (nine [22%] of 41), increased gamma-glutamyltransferase (seven [17%]), natraemia disorder (four [10%]), anaemia (four [10%]), leukopenia (four [10%]), and neutropenia (four [10%]). The frequency of patients who had serious adverse events was 44% (18 of 41) in the cetuximab group and 39% (16 of 41) in the methotrexate group. Four patients presented with a fatal adverse event in the cetuximab group (sepsis, decreased level of consciousness, pulmonary oedema, and death of unknown cause) as did two patients in the methotrexate group (dyspnoea and death of unknown cause). INTERPRETATION: The study showed no improvement in failure-free survival with cetuximab versus methotrexate. Patients with an ECOG performance status of 2 did not benefit from these systemic therapies. New treatment options including immunotherapy should be explored in frail older patients with recurrent or metastatic head and neck squamous cell carcinoma, after an initial geriatric evaluation, such as the ELAN Geriatric Evaluation. FUNDING: French programme PAIR-VADS 2011 (sponsored by the National Cancer Institute, the Fondation ARC and the Ligue Contre le Cancer), GEMLUC, GEFLUC, and Merck Santé. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Guigay J, Ortholan C, Vansteene D, et al. Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial. Lancet Healthy Longev. 2024. PMID: 38432247. doi:10.1016/S2666-7568(23)00284-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。